Disease landscape

Hodgkin Lymphoma clinical trials

Get alerts when Hodgkin Lymphoma trials change

214 active trials 119 recruiting 12 Phase 3 115 sponsors 31 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days

2026-08-28
Primary completion pushed: 2026-07 → 2026-11
Completion pushed: 2026-07 → 2026-11
NCT06383338 A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent &… · Murdoch Childrens Research Institute · Phase 1
2026-08-20
Primary completion pushed: 2027-11 → 2028-11
Completion pushed: 2029-11 → 2030-11
NCT05977673 Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma… · Fondazione Italiana Linfomi - ETS · Phase 2
2026-08-08
Primary completion pushed: 2026-08-31 → 2030-08-31
Completion pushed: 2026-08-31 → 2030-08-31
NCT05092451 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in… · M.D. Anderson Cancer Center · Phase 1/2
2026-08-07
Primary completion pushed: 2026-08-31 → 2028-08-31
Completion pushed: 2026-08-31 → 2028-08-31
NCT02861417 Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating… · M.D. Anderson Cancer Center · Phase 2
2026-08-07
Primary completion pushed: 2026-07-01 → 2028-08-03
Completion pushed: 2031-07-01 → 2033-07-01
NCT06090864 ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells · UNC Lineberger Comprehensive Cancer Center · Phase 1/2
2026-08-15
Primary completion pushed: 2026-06-30 → 2027-05-25
Completion pushed: 2026-06-30 → 2027-05-25
NCT04537871 Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study · City of Hope Medical Center
2026-09-03
Primary endpoint(s) modified
Results posted: 2026-09-02
NCT03179917 Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary… · Memorial Sloan Kettering Cancer Center · Phase 2
2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT04961515 Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous… · Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2
2026-09-02
Trial completed
Study completion confirmed: July 2026 (last estimated September 2027)
NCT01333046 Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL · Baylor College of Medicine · Phase 1
2026-08-28
Recruitment opened
Primary completion moved earlier: 2033-03-01 → 2029-12
Completion pushed: 2033-03-01 → 2033-08
NCT07256158 PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable… · Fondazione Italiana Linfomi - ETS · Phase 3
2026-08-26
Recruitment opened
NCT07551583 Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients… · M.D. Anderson Cancer Center · Phase 2
2026-08-27
Enrollment closed, study ongoing
Enrollment increased: 18 → 27 participants
NCT04288726 Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas · Baylor College of Medicine · Phase 1
2026-09-02
Results posted: 2026-09-01
NCT05508867 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice… · Merck Sharp & Dohme LLC · Phase 2
2026-08-21
Recruitment opened
NCT07021989 ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma · Michael Spinner, MD · Phase 2
2026-08-22
Recruitment opened
NCT07514819 Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma · St. Jude Children's Research Hospital
2026-08-13
Primary completion pushed: 2029-05-31 → 2029-07-31
Completion pushed: 2033-12-31 → 2034-03-31
NCT07021989 ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma · Michael Spinner, MD · Phase 2
2026-08-26
Completion pushed: 2026-06-30 → 2027-04-06
NCT03016871 Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating… · City of Hope Medical Center · Phase 2
2026-08-22
Completion pushed: 2026-07-01 → 2027-06-02
NCT03150329 Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · City of Hope Medical Center · Phase 1
2026-08-15
Completion pushed: 2026-08 → 2026-12
NCT03843294 Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma · Catherine Bollard · Phase 1

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-28 NCT07793006 New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease Indiana University new
2026-07-22 NCT07720011 Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD… Peking University People's Hospital new Phase 2
2026-07-17 NCT07710781 Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor… Ossium Health, Inc. new
2026-06-11 NCT07641010 PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma Shanghai Jiao Tong University School of Medicine new Phase 1/2

Active trials by phase

Early Phase 1
2
Phase 1
32
Phase 1/2
22
Phase 2
89
Phase 2/3
3
Phase 3
9
Phase 4
3
Not charted: 54 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 214

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT06831370 A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults… Takeda Recruiting 2026-02-23
NCT04726501 CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Children's Cancer Group, China Active, Not Recruiting 2026-03-19
NCT06761911 BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma Xiuhua Sun Not Yet Recruiting 2025-01-07
Phase 3
NCT05675410 A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs… National Cancer Institute (NCI) Recruiting 2026-09-04
NCT07256158 PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable… Fondazione Italiana Linfomi - ETS Recruiting 2026-08-27
NCT04685616 Brentuximab Vedotin in Early Stage Hodgkin Lymphoma University College, London Recruiting 2026-07-08
NCT06170489 A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected… Shanghai Junshi Bioscience Co., Ltd. Recruiting 2025-02-28
NCT04638790 First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia Recruiting 2024-09-27
NCT03907488 Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in… National Cancer Institute (NCI) Active, Not Recruiting 2026-08-04
NCT02166463 Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults… National Cancer Institute (NCI) Active, Not Recruiting 2026-07-29
NCT04459416 Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma Memorial Sloan Kettering Cancer Center Active, Not Recruiting 2025-10-20
NCT06465446 A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in… ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Not Yet Recruiting 2024-06-24
Phase 2/3
NCT06563245 Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Children's Cancer Group, China Recruiting 2026-03-19
NCT05595447 Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma Hospital Regional de Alta Especialidad del Bajio Recruiting 2025-03-12
NCT07572123 Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of… National Cancer Institute (NCI) Not Yet Recruiting 2026-07-08
Phase 2
NCT07551583 Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients… M.D. Anderson Cancer Center Recruiting 2026-08-31
NCT06745076 Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the… University of Washington Recruiting 2026-08-20
NCT07021989 ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Michael Spinner, MD Recruiting 2026-08-20
NCT07275216 Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin… City of Hope Medical Center Recruiting 2026-08-20
NCT05977673 Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma… Fondazione Italiana Linfomi - ETS Recruiting 2026-08-19
NCT03618550 Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin… Memorial Sloan Kettering Cancer Center Recruiting 2026-08-07
NCT02727803 Personalized NK Cell Therapy in CBT M.D. Anderson Cancer Center Recruiting 2026-07-30
NCT07285044 The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home… Mayo Clinic Recruiting 2026-07-30
NCT06580002 Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial University of California, Irvine Recruiting 2026-07-14
NCT06377540 MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Masonic Cancer Center, University of Minnesota Recruiting 2026-07-06
See all 214 active Hodgkin Lymphoma trials with filters →

Top sponsors by active trials in this area

City of Hope Medical Center (16) · St. Jude Children's Research Hospital (14) · M.D. Anderson Cancer Center (10) · National Cancer Institute (NCI) (9) · Memorial Sloan Kettering Cancer Center (8) · Baylor College of Medicine (6) · University of Cologne (6) · Fondazione Italiana Linfomi - ETS (5) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (4) · New York Medical College (4)

Get alerts when Hodgkin Lymphoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free